TITLE

Daunorubicin and the heart

PUB. DATE
November 1974
SOURCE
British Medical Journal;11/23/1974, Vol. 4 Issue 5942, p431
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
64322229

 

Related Articles

  • Daunorubicin/mitoxantrone.  // Reactions Weekly;7/10/2010, Issue 1309, p18 

    The article describes the case of a boy who developed dilated cardiomyopathy and heart failure while under daunorubicin and mitoxantrone treatment regimen for acute myeloid leukemia.

  • Daunorubicin/doxorubicin.  // Reactions Weekly;5/16/2009, Issue 1252, p19 

    The article presents case reports of two patients who experienced cardiogenic shock and refractory hypoxaemia after receiving daunorubicin and/or doxorubicin and both subsequently died. Patient 1, a 46-year-old woman, was treated with doxorubicin for follicular non-Hodgkin's lymphoma, and four...

  • Daunorubicin.  // Reactions Weekly;8/1/2009, Issue 1263, p15 

    The article describes the case of a young male patient who acquired severe heart failure. the patient developed the said condition while undergoing treatment for acute myeloid leukemia which included daunorubicin. The patient was subjected to a heart transplant and is now in a stable condition...

  • High-dose liposomal daunorubicin extended EFS in pediatric AML.  // Hem/Onc Today;8/10/2013, Vol. 14 Issue 15, p21 

    The article discusses research on the link of the first-line treatment with a liposomal formulation of high-dose daunorubicin to longer survival and fewer heart toxicities than standard therapy in children with acute myelogenous leukemia, referencing a study by U. Creutzig published in "Blood."

  • Daunorubicin.  // Reactions Weekly;1/12/2008, Issue 1184, p15 

    The article describes the case of a 9-year old girl who developed congestive heart failure after receiving daunorubicin for acute myeloid leukemia. Results were obtained from the patient's ECG and from a tissue Doppler imaging. Her condition improved after undergoing a resynchronization therapy...

  • Daunorubicin induces cell death via activation of apoptotic signalling pathway and inactivation of survival pathway in muscle-derived stem cells. Stulpinas, Aurimas; Imbrasaitė, Aušra; Kalvelytė, Audronė // Cell Biology & Toxicology;Apr2012, Vol. 28 Issue 2, p103 

    Daunorubicin (as well as other anthracyclines) is known to be toxic to heart cells and other cells in organism thus limiting its applicability in human cancer therapy. To investigate possible mechanisms of daunorubicin cytotoxicity, we used stem cell lines derived from adult rabbit skeletal...

  • DaunoXome approved.  // AIDS Patient Care & STDs;Aug96, Vol. 10 Issue 4, p263 

    Reports on the approval of a liposomal form of daunorubicin, a cancer chemotherapy, for the treatment of Kaposi's sarcoma in HIV-infected patients. Comparison of daunorubicin and doxorubicin; Toxicities of daunorubicin.

  • Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia. Thomas, X.; Le, Q.; Fiere, D. // Annals of Hematology;Sep2002, Vol. 81 Issue 9, p504 

    We describe three cases of acute promyelocytic leukemia (APL) with long-term disease-free survival who developed congestive heart failure (CHF) requiring cardiac transplantation. All three patients presented late-onset cardiotoxicity. Cardiac failure occurred progressively after 31-month,...

  • IGF-I in experimental daunorubicin-induced cardiomyopathy in rabbits. Geršl, V.; Cerman, J.; Šuba, P.; Mazurová, Y.; Hrdina, R.; Macháčková, J. // Human & Experimental Toxicology;1999, Vol. 18 Issue 3, p154 

    1 The occurrence of IGF-I was investigated in rabbits with experimentally daunorubicin-induced cardiomyopathy. IGF-I was measured in the heart, serum, liver and skeletal muscle. 2 A significant increase in the IGF-I was found in the left heart ventricle in daunorubicin cardiomyopathy...

  • Daunorubicin/mitoxantrone.  // Reactions Weekly;6/30/2007, Issue 1158, p12 

    The article describes the case of a boy who developed cardiotoxicity during treatment with daunorubicin and mitoxantrone for acute myeloid leukemia (AML). It references a study by J. S. Rao Mangat et al., published in the June 2007 issue of the "Journal of Heart and Lung Transplantation." The...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics